A Phase 4 interventional study of Pramipexole and Placebo in Parkinson Disease and Depression, sponsored by Boehringer Ingelheim. Completed at 77 sites in 13 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-09.
Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.
Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 11th largest by enrollment, is one of 5 that started in 2006, is one of 10 in phase 4, and was the 5th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 12 · Phase 4 10
First in 1998; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 296 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 224 across the 26 interventional studies. Of the 24 that completed or were terminated, 15 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 26 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
42 studies in Parkinson Disease by Boehringer Ingelheim: none open now, none under way, none of them phase 3. Of 42 finished, 22 (52%) have results posted.
Among the 42 studies in Parkinson Disease by Boehringer Ingelheim, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is one of 6 that started in 2006, is one of 7 in phase 4, and was the 6th registered.
Boehringer Ingelheim’s Parkinson Disease studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing pramipexole in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 42 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Parkinsons Disease (PD) is caused by a decrease of dopamine in a particular part of the brain. Dopamine is a messenger substance (neurotransmitter) that is used by the cells of the brain (nerve cells) to control and harmonize muscle movements. Consequently, the main manifestations of the disease affect movement and include tremor, muscular rigidity, slowness in performing movements and loss of balance.
However, the disease affects also other, non motor functions and may cause other disorders, such as depression. Depression may be a reaction to the disability caused by the disease, but many studies show that depression is more common in PD than in other chronic debilitating illnesses. Moreover, there is also a biological explanation for the phenomenon: dopamine is also used in brain circuits involved in the experience of pleasure, and loss of pleasure in daily physical or social activity is one of the key manifestations of depression.
The objective of the study is to assess whether pramipexole, at doses approved for the treatment of PD symptoms, is more effective than placebo in resolving depressive symptoms in PD patients.
Also data on the safety of the product in the disease will be collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A daily dose of pramipexole 0.125 mg t.i.d.; titration-to-response up to 1.0 mg t.i.d.
Drug: Pramipexole
Placebo (matching) tablets
Other: Placebo
Dopamine agonist
Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12
The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
Time frame: Baseline and Week 12
Change in BDI-IA Clinical Response (at Least 50% Reduction in Symptoms) at Week 12
BDI clinical response was defined as a reduction of ≥50% from baseline
Time frame: Week 12
Change From Baseline in the Geriatric Depression Scale-Short Form (GDS-SF) (15-item Version) Total Score at Week 12
The GDS measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 15 (worst symptoms)
Time frame: Baseline and Week 12
Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Week 12
The SHAPS measures anhedonia (inability to experience pleasure) on an ordinal scale ranging from 0 (no anhedonia) to 14 (worst anhedonia)
Time frame: Baseline and Week 12
Change From Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part I Depression Score at Week 12
The UPDRS part I depression score measures depression on an ordinal scale ranging from 0 (none) to 4 (sustained depression/suicidal thoughts)
Time frame: Baseline and Week 12
Change From Baseline in the UPDRS Part II Total Score at Week 12
Unified Parkinson's Disease Rating Scale part II total score on FAS The UPDRS part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (normal) to 52 (worst symptoms)
Time frame: Baseline and Week 12
Change From Baseline in the UPDRS Part III Total Score at Week 12
The UPDRS part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (normal) to 108 (worst symptoms)
Time frame: Baseline and Week 12
Change From Baseline in the UPDRS Part II+III Total Score at Week 12
The UPDRS part II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (normal) to 160 (worst symptoms)
Time frame: Baseline and Week 12
Clinical Global Impressions of Global Improvement (CGI-I) at Week 12
The CGI-I measures the overall improvement in the participants condition from baseline on an ordinal scale ranging from 1 (very much improved) to 7 (very much worse)
Time frame: Week 12
Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Week 12
The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)
Time frame: Baseline and Week 12
Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Week 12
This is a 5-item patient reported measure of health status developed for use in evaluating health and healthcare. It produces a numeric score for health status on which full health has a value of 1 and death has a value of 0. Euro-QOL describes health status in terms of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)
Time frame: Baseline and Week 12
Change From Baseline to End of Maintenance Phase in European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Pain Score at Week 12
The VAS is a method used for the measurement of pain. The patient is asked to place a mark on an uncalibrated (usually 0 - 10 cm) line representing the patient's degree of general pain. The two extremities of the line were taken to represent 'no pain' and 'unbearable pain', respectively. VAS pain scores could range from 0 (no pain) to 100 (unbearable pain).
Time frame: Baseline and Week 12
Change From Baseline in the UPDRS Part I Total Score at Week 12
The UPDRS part I total score measures depression on an ordinal scale ranging from 0 to 16. UPDRS Part I total scores could range from 0 to 16; where higher scores were indicative of worse symptoms.
Time frame: Baseline and Week 12
Change From Baseline in the UPDRS Part IV Total Score at Week 12
The UPDRS Part IV measures motor complications (dyskinesia) and the total score could range from 0 to 23; where higher scores were indicative of worse symptoms.
Time frame: Baseline and Week 12
Abnormal Findings: Clinical Laboratory Evaluations (Biochemistry and Haematology)and Vital Signs
Time frame: Baseline and Week 12
| Milestone | Placebo | Pramipexole |
|---|---|---|
| Started | 152 | 144 |
| Completed | 133 | 124 |
| Not completed | 19 | 20 |
| Withdrew: Adverse event | 16 | 10 |
| Withdrew: Withdrawal by subject | 1 | 5 |
| Withdrew: Lack of efficacy | 2 | 1 |
| Withdrew: Non-compliant with trial protocol | 0 | 3 |
| Withdrew: Other | 0 | 1 |
The BDI measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 63 (worst symptoms)
| Score on scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in the Beck Depression Inventory-Version 1A (BDI-IA) Total Score at Week 12 | -4 ± 0.5 | -5.9 ± 0.5 |
BDI clinical response was defined as a reduction of ≥50% from baseline
| participants | Placebo | Pramipexole |
|---|---|---|
| Change in BDI-IA Clinical Response (at Least 50% Reduction in Symptoms) at Week 12 | 27 | 38 |
The GDS measures symptoms of depression on an ordinal scale ranging from 0 (no symptoms) to 15 (worst symptoms)
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in the Geriatric Depression Scale-Short Form (GDS-SF) (15-item Version) Total Score at Week 12 | -1.7 ± 0.3 | -2.5 ± 0.3 |
The SHAPS measures anhedonia (inability to experience pleasure) on an ordinal scale ranging from 0 (no anhedonia) to 14 (worst anhedonia)
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Week 12 | 0 (-2 to 0) | 0 (-2 to 0) |
The UPDRS part I depression score measures depression on an ordinal scale ranging from 0 (none) to 4 (sustained depression/suicidal thoughts)
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in the Unified Parkinson's Disease Rating Scale (UPDRS) Part I Depression Score at Week 12 | -1 (-1 to 0) | -1 (-2 to 0) |
Unified Parkinson's Disease Rating Scale part II total score on FAS The UPDRS part II total score measures the impact of PD on activities of daily living on an ordinal scale ranging from 0 (normal) to 52 (worst symptoms)
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in the UPDRS Part II Total Score at Week 12 | -1.2 ± 0.3 | -2.4 ± 0.3 |
The UPDRS part III total score measures the impact of PD on motor skills on an ordinal scale ranging from 0 (normal) to 108 (worst symptoms)
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in the UPDRS Part III Total Score at Week 12 | -2.2 ± 0.5 | -4.4 ± 0.6 |
The UPDRS part II+III total score measures the impact of PD on activities of daily living and motor skills on an ordinal scale ranging from 0 (normal) to 160 (worst symptoms)
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in the UPDRS Part II+III Total Score at Week 12 | -3.4 ± 0.7 | -6.8 ± 0.7 |
The CGI-I measures the overall improvement in the participants condition from baseline on an ordinal scale ranging from 1 (very much improved) to 7 (very much worse)
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Clinical Global Impressions of Global Improvement (CGI-I) at Week 12 | 3 (1 to 6) | 3 (1 to 6) |
The PDQ-39 measures aspects of health in PD participants, the overall index score is the mean of the eight individual domain scores measured on a continuous scale ranging from 0 (no problem at all) to 100 (maximum level of the problem)
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in the Parkinson's Disease Questionnaire-39 (PDQ-39) Overall Index Score at Week 12 | -2.4 (-8.9 to 2.6) | -3.3 (-8.9 to 0.3) |
This is a 5-item patient reported measure of health status developed for use in evaluating health and healthcare. It produces a numeric score for health status on which full health has a value of 1 and death has a value of 0. Euro-QOL describes health status in terms of 5 dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. The EQ-5D measures health status on a continuous scale ranging from 0 (dead) to 1 (full health)
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in the European Quality of Life Scale (EUROQOL (EQ)-5D) Overall Index Score at Week 12 | 0 (-0.06 to 0.12) | 0.07 (0 to 0.21) |
The VAS is a method used for the measurement of pain. The patient is asked to place a mark on an uncalibrated (usually 0 - 10 cm) line representing the patient's degree of general pain. The two extremities of the line were taken to represent 'no pain' and 'unbearable pain', respectively. VAS pain scores could range from 0 (no pain) to 100 (unbearable pain).
| mm | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline to End of Maintenance Phase in European Quality of Life Visual Analogue Scale (EUROQOL (EQ) VAS) Pain Score at Week 12 | -3 ± 1.8 | -3.5 ± 1.9 |
The UPDRS part I total score measures depression on an ordinal scale ranging from 0 to 16. UPDRS Part I total scores could range from 0 to 16; where higher scores were indicative of worse symptoms.
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in the UPDRS Part I Total Score at Week 12 | -1.0 (-1.0 to 0.0) | -1.0 (-2.0 to 0.0) |
The UPDRS Part IV measures motor complications (dyskinesia) and the total score could range from 0 to 23; where higher scores were indicative of worse symptoms.
| units on a scale | Placebo | Pramipexole |
|---|---|---|
| Change From Baseline in the UPDRS Part IV Total Score at Week 12 | -0.2 ± 0.1 | -0.3 ± 0.1 |
| participants | Placebo | Pramipexole |
|---|---|---|
| Hypotension | 1 | 1 |
| Orthostatic hypotension | 1 | 0 |
Collected over First drug intake up to 48 hours after the last drug intake. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | — | — |
| Pramipexole | — | — | — |
| Event | Placebo | Pramipexole |
|---|---|---|
| EndocarditisInfections and infestations | 0/152 | 1/144 |
| HyperlipidaemiaMetabolism and nutrition disorders | 0/152 | 1/144 |
| HallucinationPsychiatric disorders | 0/152 | 1/144 |
| Cerebral haemorrhageNervous system disorders | 0/152 | 1/144 |
| Cerebrovascular accidentNervous system disorders | 0/152 | 1/144 |
| SyncopeNervous system disorders | 0/152 | 1/144 |
| Cardiac failureCardiac disorders | 1/152 | 1/144 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/152 | 1/144 |
| AnuriaRenal and urinary disorders | 0/152 | 1/144 |
| FallInjury, poisoning and procedural complications | 1/152 | 1/144 |
| Event | Placebo | Pramipexole |
|---|---|---|
| NauseaGastrointestinal disorders | 26/152 | 24/144 |
| DizzinessNervous system disorders | 9/152 | 16/144 |
| HeadacheNervous system disorders | 12/152 | 16/144 |
| SomnolenceNervous system disorders | 12/152 | 15/144 |
| DyskinesiaNervous system disorders | 4/152 | 10/144 |
| VertigoEar and labyrinth disorders | 4/152 | 10/144 |
| FatigueGeneral disorders | 9/152 | 8/144 |
| InsomniaPsychiatric disorders | 4/152 | 8/144 |
| Age, Continuous(Years) | Placebo | Pramipexole | Total |
|---|---|---|---|
| Mean | 66.6 ± 9.9 | 67.4 ± 9.0 | 67 ± 9.5 |
| Sex: Female, Male(Participants) | Placebo | Pramipexole | Total |
|---|---|---|---|
| Female | 74 | 82 | 156 |
| Male | 78 | 62 | 140 |
The record gives a start of Mar 2006 and a primary completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole